EA200800555A1 - Производные ксантина в качестве селективных агонистов hm74a - Google Patents

Производные ксантина в качестве селективных агонистов hm74a

Info

Publication number
EA200800555A1
EA200800555A1 EA200800555A EA200800555A EA200800555A1 EA 200800555 A1 EA200800555 A1 EA 200800555A1 EA 200800555 A EA200800555 A EA 200800555A EA 200800555 A EA200800555 A EA 200800555A EA 200800555 A1 EA200800555 A1 EA 200800555A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
hm74a
xanthine
selective agonists
compounds
Prior art date
Application number
EA200800555A
Other languages
English (en)
Other versions
EA014556B1 (ru
Inventor
Ричард Джонатан Дэниэл Хэтли
Эндрю МакМертри Мэйсон
Иван Лео Пинто
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of EA200800555A1 publication Critical patent/EA200800555A1/ru
Publication of EA014556B1 publication Critical patent/EA014556B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Abstract

Настоящее изобретение относится к соединениям формулы (I), которые являются производными ксантина, способам получения указанных производных, фармацевтическим композициям, содержащим эти соединения, и применению соединений в терапии, например, в лечении заболеваний, при которых предактивация рецептора НМ74А могла бы иметь эффект в отношении заболевания, или при которых активация рецептора будет эффективной.
EA200800555A 2005-08-10 2006-08-08 Производные ксантина в качестве селективных агонистов hm74a EA014556B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
PCT/EP2006/007865 WO2007017261A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (2)

Publication Number Publication Date
EA200800555A1 true EA200800555A1 (ru) 2008-08-29
EA014556B1 EA014556B1 (ru) 2010-12-30

Family

ID=37189397

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200800564A EA200800564A1 (ru) 2005-08-10 2006-08-08 Производные ксантина как селективные агонисты нм74а
EA200800555A EA014556B1 (ru) 2005-08-10 2006-08-08 Производные ксантина в качестве селективных агонистов hm74a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200800564A EA200800564A1 (ru) 2005-08-10 2006-08-08 Производные ксантина как селективные агонисты нм74а

Country Status (29)

Country Link
US (3) US8143264B2 (ru)
EP (3) EP1912991B1 (ru)
JP (2) JP2009504592A (ru)
KR (2) KR20080034993A (ru)
AR (1) AR055369A1 (ru)
AT (1) ATE487719T1 (ru)
AU (2) AU2006278215A1 (ru)
BR (2) BRPI0614270A2 (ru)
CA (2) CA2618963A1 (ru)
CR (2) CR9749A (ru)
CY (1) CY1111757T1 (ru)
DE (1) DE602006018151D1 (ru)
DK (1) DK1912991T3 (ru)
EA (2) EA200800564A1 (ru)
ES (1) ES2401128T3 (ru)
HK (1) HK1116779A1 (ru)
HR (1) HRP20100725T1 (ru)
IL (2) IL189081A0 (ru)
MA (2) MA29692B1 (ru)
MX (2) MX2008001931A (ru)
MY (1) MY142067A (ru)
NO (2) NO20081212L (ru)
NZ (1) NZ565494A (ru)
PE (1) PE20070405A1 (ru)
PL (1) PL1912991T3 (ru)
PT (1) PT1912991E (ru)
SI (1) SI1912991T1 (ru)
TW (1) TW200800217A (ru)
WO (2) WO2007017261A1 (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
KR101100601B1 (ko) 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的hm74aアゴニストとしてのキサンチン誘導体
DE602007010312D1 (de) 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten
EP2044074A2 (en) 2006-06-23 2009-04-08 Incyte Corporation Purinone derivatives as hm74a agonists
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2606045B1 (en) * 2010-08-16 2016-01-06 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
US8580825B2 (en) * 2010-09-23 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201492069A1 (ru) * 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
US9359359B2 (en) * 2013-03-15 2016-06-07 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
WO2014182943A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
CN104211702B (zh) * 2013-05-29 2018-08-31 中国医学科学院药物研究所 取代黄嘌呤类化合物及其制备方法和用途
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ.ホフマン-ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
WO2023150592A2 (en) * 2022-02-03 2023-08-10 D.E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO1993017684A2 (en) 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US6780865B1 (en) * 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1171442B1 (en) 1999-04-09 2005-12-07 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signalling inhibitors
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
EP1404675B1 (en) * 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
KR101100601B1 (ko) * 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006045565A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
US20080221108A1 (en) * 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的hm74aアゴニストとしてのキサンチン誘導体
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
AU2009324811B2 (en) 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
EP1912991B1 (en) 2010-11-10
AU2006278216A1 (en) 2007-02-15
EA014556B1 (ru) 2010-12-30
IL189081A0 (en) 2008-08-07
EP1912992A1 (en) 2008-04-23
ATE487719T1 (de) 2010-11-15
US20100179128A1 (en) 2010-07-15
KR20080038396A (ko) 2008-05-06
PE20070405A1 (es) 2007-05-06
BRPI0614270A2 (pt) 2011-03-22
DE602006018151D1 (de) 2010-12-23
HRP20100725T1 (hr) 2011-01-31
EP1912991A1 (en) 2008-04-23
JP2009504591A (ja) 2009-02-05
AU2006278215A1 (en) 2007-02-15
MY142067A (en) 2010-08-30
DK1912991T3 (da) 2011-02-21
SI1912991T1 (sl) 2011-03-31
CA2618963A1 (en) 2007-02-15
WO2007017262A1 (en) 2007-02-15
CR9748A (es) 2008-05-05
US8143264B2 (en) 2012-03-27
NZ565494A (en) 2011-06-30
BRPI0615145A2 (pt) 2009-11-03
NO20081212L (no) 2008-05-06
HK1116779A1 (en) 2009-01-02
NO20081211L (no) 2008-05-08
WO2007017261A1 (en) 2007-02-15
MA29692B1 (fr) 2008-08-01
CR9749A (es) 2008-05-22
PT1912991E (pt) 2011-01-17
PL1912991T3 (pl) 2011-04-29
EA200800564A1 (ru) 2008-08-29
CA2626723A1 (en) 2007-02-15
KR20080034993A (ko) 2008-04-22
MX2008001929A (es) 2008-03-24
MX2008001931A (es) 2008-03-24
TW200800217A (en) 2008-01-01
US20110257205A1 (en) 2011-10-20
AR055369A1 (es) 2007-08-22
US20100168122A1 (en) 2010-07-01
CY1111757T1 (el) 2015-10-07
IL189083A0 (en) 2008-08-07
EP2272848B1 (en) 2012-12-26
EP2272848A1 (en) 2011-01-12
ES2401128T3 (es) 2013-04-17
MA29693B1 (fr) 2008-08-01
JP5112316B2 (ja) 2013-01-09
JP2009504592A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
TW200606162A (en) Pyrazolopyridine derivatives
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
TW200611695A (en) Pyrrolopyridine derivatives
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA200601894A1 (ru) Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
GB0524814D0 (en) Compounds
MY150098A (en) Benzylpiperazine derivates and their medical use
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU